Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathumthani, Thailand.
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thammasat University (Rangsit Campus), Pathumthani, Thailand.
J Evid Based Integr Med. 2023 Jan-Dec;28:2515690X231191101. doi: 10.1177/2515690X231191101.
Psoriasis is an incurable, chronic and auto-immune skin disorder with a global prevalence rate of approximately 2-3%. The study investigated the antipsoriasis activities of Deprungsith formulation and its bioactive components and their potential for inhibitory activities on human cytochrome P450 (CYP450). HaCaT and peripheral blood mononuclear cells (PBMCs) from healthy volunteers (n = 9) and psoriasis patients (n = 10) were exposed to Deprungsith formulation (Thai traditional medicine for psoriasis consisting of 16 plants), ethyl p-methoxycinnamate (EPMC), ligustilide and cyclosporin for 24 and 48 h. The antiproliferative, cell apoptosis and cell cycle arrest activities were evaluated using MTT assay and flow cytometry, respectively. The pro-inflammatory cytokine mRNA expression levels were measured using real-time polymerase chain reaction (RT-PCR). The CYP450 inhibitory effect was investigated using a bioluminescent-based CYP450 assay. Deprungsith formulation and the bioactive compounds inhibited HaCaT cells and PBMCs with weak to moderate potencies. EPMC and ligustilide combination produced an additive effect. Most substances arrested cell transition at sub-G and S phases, leading to early and late apoptosis induction. With prolonged exposure (48 h), all test substances decreased PBMCs necrosis. The mRNA expression of all pro-inflammatory cytokines was downregulated. Deprungsith formulation, EPMC, ligustilide and ferulic acid inhibited CYP1A2, CYP2C9, CYP2D6 and CYP3A4 activities with weak to moderate potencies. Deprungsith formulation and bioactive components induced cell apoptosis by inhibiting cell transition at specific cell cycle phases, which was correlated with the mRNA downregulation of interleukin (IL-6, IL-12p19, IL-23) and tumor necrosis factor (TNF-α). There is a low risk of potential adverse drug reactions and toxicity due to CYP450 interaction when Deprungsith formulation is concurrently administered with modern medicines.
银屑病是一种无法治愈的慢性自身免疫性皮肤病，全球患病率约为 2-3%。本研究调查了 Deprungsith 配方及其生物活性成分的抗银屑病活性及其对人细胞色素 P450（CYP450）抑制活性的潜力。将 Deprungsith 配方（由 16 种植物组成的泰国传统银屑病药物）、乙基对甲氧基肉桂酸（EPMC）、藁本内酯和环孢菌素暴露于健康志愿者（n=9）和银屑病患者（n=10）的 HaCaT 和外周血单核细胞（PBMC）中 24 和 48 小时。使用 MTT 测定法评估增殖抑制、细胞凋亡和细胞周期阻滞活性，分别使用实时聚合酶链反应（RT-PCR）测量促炎细胞因子 mRNA 表达水平。使用基于生物发光的 CYP450 测定法研究 CYP450 抑制作用。Deprungsith 配方和生物活性化合物以弱至中等强度抑制 HaCaT 细胞和 PBMC。EPMC 和藁本内酯组合产生相加作用。大多数物质将细胞转化阻滞在 sub-G 和 S 期，导致早期和晚期凋亡诱导。随着暴露时间延长（48 小时），所有测试物质均降低了 PBMC 坏死。所有促炎细胞因子的 mRNA 表达均下调。Deprungsith 配方、EPMC、藁本内酯和阿魏酸以弱至中等强度抑制 CYP1A2、CYP2C9、CYP2D6 和 CYP3A4 活性。Deprungsith 配方和生物活性成分通过抑制特定细胞周期阶段的细胞转化诱导细胞凋亡，这与白细胞介素（IL-6、IL-12p19、IL-23）和肿瘤坏死因子（TNF-α）的 mRNA 下调相关。Deprungsith 配方与现代药物同时使用时，由于 CYP450 相互作用，潜在不良反应和毒性的风险较低。
